Premium
Cimetidine and Granulopoiesis: Bone Marrow Culture Studies in Normal Man and Patients with Cimetidine‐associated Neutropenia
Author(s) -
Fitchen J. H.,
Koeefler H. P.
Publication year - 1980
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1980.tb05982.x
Subject(s) - cimetidine , granulopoiesis , bone marrow , medicine , neutropenia , metiamide , pharmacology , granulocyte , microgram , leukopenia , immunology , histamine h2 receptor , in vitro , chemistry , receptor , progenitor cell , toxicity , biology , stem cell , antagonist , biochemistry , genetics
S ummary We studied the effect of the H 2 ‐receptor antagonists, cimetidine and metiamide, on in vitro myeloid colony formation by bone marrow cells from seven normal volunteers and two patients with a cimetidine‐associated neutropenia. A cimetidine concentration of 500 μg/ml produced 50% inhibition of normal granulocyte—macrophage colony formation, and 1000 μg/ml of cimetidine completely suppressed proliferation. The inhibitory effect of metiamide occurred at lower concentrations: 50% inhibition at 250 μg/ml and 95% inhibition at 350 μg/ml. Cimetidine had a similar inhibitory effect on colony formation by recovery marrow from the two patients with cimetidine‐associated neutropenia. Treatment of autologous and allogeneic marrows with patients’ acute phase sera and cimetidine failed to show evidence of antibody‐mediated suppression of granulopoiesis. Our results indicate that at sufficiently high concentrations, cimetidine and metiamide inhibit human bone marrow myeloid colony formation in vitro . These findings are consistent with the hypothesis that H 2 ‐receptor antagonists may produce neutropenia in a dose‐related fashion by injury to granulocytic progenitor cells in vivo .